European Commission gives pharma, medtech industry opportunity for say on HTA network
This article was originally published in Clinica
Executive Summary
The European Commission is seeking feedback from drug and medical device companies and other interested parties on creating a network of national health technology appraisal bodies, as outlined in the cross border healthcare directive. The commission's musings are general at this stage, but the consultation hints at areas that might affect the way that national HTA agencies work and how far industry and other stakeholders might be involved, says EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.